This distributed development company creates new therapeutic interventions by targeting specific biological drivers of aging. They establish Affiliate Companies to advance scientific inventions aimed at treating specific diseases first, with the goal of later using these as preventative medicines. The company manages a diverse pipeline across multiple therapeutic areas, including cardiometabolic, fibrotic, and oncological indications.
Funding
Funding not disclosed
Founders
Product
Problem
As humans age, their immune function declines, increasing susceptibility to infections and reducing the effectiveness of vaccines. Current rapalogs, while showing promise in extending lifespan, often have safety and efficacy limitations due to their non-selective inhibition of mTOR complexes.
Solution
Tornado Therapeutics is developing a portfolio of next-generation rapalogs designed to selectively inhibit the TORC1 complex, a key regulator of aging and immune function. By targeting TORC1 specifically, Tornado's compounds aim to enhance protective pathways and prevent overactive mTOR cell signaling, potentially leading to improved safety and efficacy compared to existing rapalogs. Their lead asset is progressing through IND-enabling studies, with a second asset undergoing preclinical efficacy testing. These novel rapalogs are being developed for multiple clinical indications, including viral respiratory tract infections, oncology, autoimmune diseases, and dermatology.
Target Audience
The primary target audience includes individuals at risk of age-related immune dysfunction, as well as those suffering from viral respiratory tract infections, cancer, autoimmune diseases, and dermatological conditions.
Features
- Selective TORC1 inhibition to upregulate protective pathways and prevent overactive mTOR signaling
- Composition of matter patent protection for novel rapalogs
- Multiple compounds in the pipeline targeting various aging-related diseases
- Lead asset progressing through IND-enabling studies
- Second asset undergoing preclinical efficacy testing
- More potent inhibitors of TORC1 and TORC2 for autoimmune diseases and cancer